Glioblastoma News and Research

RSS

Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.

Clinical data from two separate Phase 2a combination drug studies of Azixa presented at ASCO 2010

Myriad Pharmaceuticals, Inc. today announced the presentation of clinical data from two separate Phase 2a combination drug studies of AzixaTM (MPC-6827, verubulin) at the American Society of Clinical Oncology 2010 Annual Meeting in Chicago, IL. Results from studies in both recurrent glioblastoma multiforme and stage 4 metastatic melanoma demonstrated that Azixa, in combination with standard treatments, resulted in durable responses with no added toxicity compared with chemotherapy alone.

8 Jun 2010

Angiochem presents positive Phase 1/2 clinical data of ANG1005 for brain cancer at ASCO 2010

Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB) through LRP-1 targeting, announced today that complete phase 1/2 clinical data in two clinical studies of its lead oncology program, ANG1005, for the treatment of brain cancers, including glioblastoma (GBM) and brain metastases, were presented at the 2010 American Society for Clinical Oncology (ASCO) Annual Meeting, June 4-8, in Chicago, IL.

7 Jun 2010

CytRx granted U.S. Patent for bafetinib

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the granting by the U.S. Patent and Trademark Office (USPTO) of U.S. Patent 7,728,131 for oncology drug candidate bafetinib, encompassing claims related to bafetinib's pharmaceutical compound and composition in all indications, as well as for use in methods for treating acute and chronic myelogenous leukemia and acute lymphoblastic leukemia.

7 Jun 2010

PTC receives $5.4M SDD Award to support development of drugs that target Bmi-1

PTC Therapeutics, Inc. today announced the receipt of a $5.4 million Seeding Drug Discovery Award from The Wellcome Trust to support the development of drugs that target Bmi-1, a protein that has been linked to drug resistant cancers.

7 Jun 2010

Merck Serono reports long-term follow-up data of cilengitide Phase II study for recurrent glioblastoma

Merck Serono, a division of Merck KGaA, Darmstadt, Germany announced today that long-term follow-up data of a randomized Phase II study of two cilengitide doses in recurrent glioblastoma were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

7 Jun 2010

Exelixis reports updated interim data from trials of XL765 small molecule inhibitor of PI3K and mTOR

Exelixis, Inc. today reported updated interim data from three ongoing trials of XL765 (SAR245409), an orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mTOR. Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy.

7 Jun 2010

Celldex reports interim positive results from rindopepimut Phase 2b study for GBM at ASCO

Celldex Therapeutics, Inc. today announced that interim results from a Phase 2b study evaluating rindopepimut (formerly PF-04948568 or CDX-110) in newly-diagnosed glioblastoma multiforme (GBM) patients were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).

7 Jun 2010

AVEO's initiation of SCH 900105 Phase 2 trial in non-small cell lung cancer triggers $8.5M milestone payment

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated a Phase 2 clinical trial evaluating SCH 900105 (also referred to as AV-299) for the treatment of non-small cell lung cancer. The initiation of this trial triggers an $8.5 million milestone payment by Merck to AVEO resulting from a 2007 agreement between AVEO and Schering-Plough (now Merck).

7 Jun 2010

Positive phase III clinical trial data of NovoCure's NovoTTF device for recurrent GBM presented at ASCO

Data from the first phase III clinical trial of NovoCure's NovoTTF device for treatment of patients with recurrent glioblastoma (GBM) were presented today as a late breaking abstract during the Neuro-Oncology session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Study results show that NovoTTF, a novel, non-invasive, portable medical device, may be as or more effective than the best available chemotherapies for GBM, but without the toxicity usually associated with cytotoxic or targeted treatments.

7 Jun 2010

Data on ImmunoCellular Therapeutics' ICT-107 for GBM to be presented at 46th ASCO

ImmunoCellular Therapeutics, Ltd. a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that data from a recent clinical trial of ICT-107, the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), will be presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 4-8 in Chicago.

2 Jun 2010

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced initiation of a Phase 2 proof-of-concept clinical trial to evaluate the preliminary efficacy and safety of its oncology drug candidate bafetinib in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL).

29 May 2010

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its drug candidate bafetinib (formerly known as INNO-406) demonstrated statistically significant inhibition of glioblastoma multiforme cell lines in a preclinical trial. Glioblastoma multiforme is the most common and aggressive primary adult brain tumor.

28 May 2010

Sangamo's ZFP Therapeutics technology highlighted at ASGCT Annual Meeting

Sangamo BioSciences, Inc. announced today that data from research and preclinical programs focused on the development of zinc finger DNA-binding protein Therapeutics were described in fifteen presentations given by Sangamo scientists and collaborators at the 13th Annual Meeting of the American Society of Gene and Cell Therapy.

24 May 2010

ImmunoCellular Therapeutics to present clinical results of ICT-107 dendritic cell immunotherapy at 46th ASCO

ImmunoCellular Therapeutics, Ltd. a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that it will be presenting results from its clinical trial of ICT-107 at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 4-8 in Chicago.

21 May 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Pfizer Oncology will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology meeting in Chicago from June 4-8.

21 May 2010

Exelixis reports interim data from XL184 phase 2 trial for recurrent glioblastoma at ASCO 2010

Exelixis, Inc. today reported promising interim data from an ongoing phase 2 trial of XL184 in patients with recurrent glioblastoma (GB), the most common and aggressive form of brain cancer. Dr. Patrick Wen from the Dana Farber Cancer Institute in Boston, MA will present the data in an Oral Session (Abstract #2006) on Saturday, June 5 at 5:00 p.m. at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

Phase 1/2 clinical trial data of Oncophage for recurrent high-grade glioma

Antigenics today announced that data from a multi-center Phase 1/2 clinical trial of Oncophage (vitespen) for recurrent high-grade glioma (brain cancer) was presented at the International Conference on Brain Tumor Research and Therapy. The study was conducted by the Brain Tumor Research Center at the University of California, San Francisco.

20 May 2010

Canadian Cancer Statistics 2010 focuses on care, support for dying patients

The type and quality of care and services to ensure a cancer patient dies with dignity in the setting of their choice depends on where the person lives in Canada, according to a special report about end-of-life care in Canadian Cancer Statistics 2010, released today by the Canadian Cancer Society.

20 May 2010

IMUC, Torrey Pines Institute identify peptides that generate CD-133 specific T-cells

ImmunoCellular Therapeutics, a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that the Company and Torrey Pines Institute for Molecular Studies in San Diego, CA have identified several peptides which can generate CD-133 specific T-cells. CD-133 is found in high abundance on cancer stem cells ("CSCs") which makes it promising for immunological targeting.

18 May 2010

Exelixis first-quarter revenues increase to $42.2 million

Exelixis, Inc. today reported financial results for the first quarter ended March 31, 2010.

12 May 2010

Glioblastoma News and Research

Further Reading

Clinical data from two separate Phase 2a combination drug studies of Azixa presented at ASCO 2010

Angiochem presents positive Phase 1/2 clinical data of ANG1005 for brain cancer at ASCO 2010

CytRx granted U.S. Patent for bafetinib

PTC receives $5.4M SDD Award to support development of drugs that target Bmi-1

Merck Serono reports long-term follow-up data of cilengitide Phase II study for recurrent glioblastoma

Exelixis reports updated interim data from trials of XL765 small molecule inhibitor of PI3K and mTOR

Celldex reports interim positive results from rindopepimut Phase 2b study for GBM at ASCO

AVEO's initiation of SCH 900105 Phase 2 trial in non-small cell lung cancer triggers $8.5M milestone payment

Positive phase III clinical trial data of NovoCure's NovoTTF device for recurrent GBM presented at ASCO

Data on ImmunoCellular Therapeutics' ICT-107 for GBM to be presented at 46th ASCO

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

Sangamo's ZFP Therapeutics technology highlighted at ASGCT Annual Meeting

ImmunoCellular Therapeutics to present clinical results of ICT-107 dendritic cell immunotherapy at 46th ASCO

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Exelixis reports interim data from XL184 phase 2 trial for recurrent glioblastoma at ASCO 2010

Phase 1/2 clinical trial data of Oncophage for recurrent high-grade glioma

Canadian Cancer Statistics 2010 focuses on care, support for dying patients

IMUC, Torrey Pines Institute identify peptides that generate CD-133 specific T-cells

Exelixis first-quarter revenues increase to $42.2 million

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News